Human CellExp CD85J/LILRB1, human recombinant protein
CD85J, LILRB1, CD85, ILT2, LIR1, MIR7
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8NHL6 |
---|---|
Calculated MW | This protein is fused with Fc fragment of human IgG1 at the C-terminus, has a calculated MW of 73.8 kDa. The predicted N-terminus is Gly 24. DTT-reduced Protein migrates as 90-110 kDa due to glycosylation. |
Gene ID | 10859 |
---|---|
Gene Symbol | LILRB1 |
Other Names | CD85J, LILRB1, CD85, ILT2, LIR1, MIR7 |
Gene Source | Human |
Source | HEK293 cells |
Assay&Purity | SDS-PAGE; ≥95% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Results | Measured by its ability to support the adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells. Immobilized rhCD85J / LILRB1 Fc Chimera at 10 µg/mL, 100 µL/well can support 60-80% HSB2 cell adhesion, when 100000 cells were added in each well of a 96-well plate. |
Target/Specificity | CD85J/LILRB1 |
Application Notes | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
Format | Lyophilized |
Storage | -20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CD85 antigen-like family member J (CD85J) also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family. CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes. CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
References
Wagtmann N.,et al.Curr. Biol. 7:615-618(1997).
Cosman D.,et al.Immunity 7:273-282(1997).
Liu W.R.,et al.Immunogenetics 51:659-669(2000).
Jones D.C.,et al.Eur. J. Immunol. 39:3195-3206(2009).
Davidson C.L.,et al.Hum. Immunol. 71:942-949(2010).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.